Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

The Lancet 2026 Open access

Read full text
Authors: Domenica Lorusso, Laurence Gladieff, David M O'Malley, Jae-Weon Kim, Gabriel Garbaos, Anna Fagotti, Lucy Gilbert, Linda Mileshkin, Stanislas Quesada, Elizabeth Hopp, Yong Jae Lee, Ana Oaknin
+29 more Mariana Scaranti, Byoung-Gie Kim, Andrew Clamp, Christina Prillaman, Connie I. Diakos, Andrea Bagaméri, Aliza Leiser, Vanda Salutari, Bradley J Monk, Philippe Follana, C. McClung, Vittoria Carbone, Brian Slomovitz, Elena Giudice, Maria Chiara Cannizzaro, Laurène Gavoille, Alix Devaux, Paolo Scollo, Giuseppa Scandurra, Chiara Cassani, Grazia Artioli, Toon Van Gorp, Ana Santaballa, Lyndah Dreiling, Amanda Kesner-Hays, Iulia Cristina Tudor, Adrian M. Jubb, Nicoletta Colombo, Alexander B Olawaiye
DOI: 10.1016/s0140-6736(26)00462-9
Cited by: 12
References: 39

Abstract

BACKGROUND: Relacorilant is a selective glucocorticoid receptor antagonist that increases the sensitivity of many cancer cell types to chemotherapy. The efficacy and safety of relacorilant plus nab-paclitaxel were assessed in the phase 3 ROSELLA (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223) trial; the combination showed significant improvement in progression-free survival among patients with platinum-resistant ovarian cancer compared with nab-paclitaxel monotherapy. Results of the final overall survival analysis are reported here. METHODS: intravenously on the aforementioned schedule). Patients, aged 18 years or older, with one to three lines of previous anticancer therapy and platinum-resistant disease (progression

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Intraperitoneal and Appendiceal Malignancies

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10538
Pages
1513–1524
Publication date
1 April 2026
Language
EN